Assessing Heterogeneity of Treatment Effect in Real-World Data.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
Apr 2023
Historique:
medline: 21 3 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

Increasing availability of real-world data (RWD) generated from patient care enables the generation of evidence to inform clinical decisions for subpopulations of patients and perhaps even individuals. There is growing opportunity to identify important heterogeneity of treatment effects (HTE) in these subgroups

Identifiants

pubmed: 36940440
doi: 10.7326/M22-1510
pmc: PMC10273137
mid: NIHMS1896428
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

536-544

Subventions

Organisme : NIA NIH HHS
ID : K01 AG073651
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL139426
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG049036
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG070661
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

J Biopharm Stat. 2014;24(1):110-29
pubmed: 24392981
Am J Epidemiol. 2006 Feb 1;163(3):262-70
pubmed: 16371515
Trials. 2010 Aug 12;11:85
pubmed: 20704705
J Clin Epidemiol. 2005 Jan;58(1):26-40
pubmed: 15649668
Epidemiology. 2008 Nov;19(6):766-79
pubmed: 18854702
Ann Intern Med. 2020 Jan 7;172(1):35-45
pubmed: 31711134
J Clin Epidemiol. 2013 Aug;66(8):818-25
pubmed: 23651763
Stat Med. 2018 May 20;37(11):1767-1787
pubmed: 29508417
J Am Stat Assoc. 2014 Oct;109(508):1517-1532
pubmed: 25729117
Diabetes Obes Metab. 2019 Nov;21(11):2394-2404
pubmed: 31264755
BMJ. 2016 Jan 25;352:i6
pubmed: 26810254
N Engl J Med. 2007 May 10;356(19):1915-27
pubmed: 17494925
Stat Med. 2011 Sep 20;30(21):2601-21
pubmed: 21786278
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4156-4165
pubmed: 30770453
J Consult Clin Psychol. 2014 Oct;82(5):773-83
pubmed: 24731233
Arch Intern Med. 1974 Dec;134(6):1064-7
pubmed: 4433187
Lancet. 2005 Jan 8-14;365(9454):176-86
pubmed: 15639301
J Clin Invest. 2020 Feb 3;130(2):565-574
pubmed: 32011317
J Chronic Dis. 1987;40 Suppl 2:139S-161S
pubmed: 3667861
Health Serv Outcomes Res Methodol. 2016;16(4):213-233
pubmed: 27881932
Trials. 2008 May 22;9:30
pubmed: 18498644
Stat Med. 2013 Dec 10;32(28):4906-23
pubmed: 23788362
Eur J Epidemiol. 2011 Oct;26(10):825-6; author reply 826
pubmed: 21892791
Am J Epidemiol. 2007 Nov 1;166(9):985-93
pubmed: 17875580
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Stat Med. 2013 Aug 30;32(19):3373-87
pubmed: 23526267
Am J Epidemiol. 2016 Apr 15;183(8):758-64
pubmed: 26994063
Clin Neurol Neurosurg. 2022 Nov;222:107469
pubmed: 36228442
Ann Intern Med. 1992 Jan 1;116(1):78-84
pubmed: 1530753
Stat Med. 1989 Jun;8(6):679-701
pubmed: 2749074
Eur J Epidemiol. 2011 Jun;26(6):433-8
pubmed: 21344323
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-1039
pubmed: 28913966
Clin Cancer Res. 2020 Jul 15;26(14):3671-3681
pubmed: 32345648
HIV Med. 2021 May;22(5):325-333
pubmed: 33247876
Clin Pharmacol Ther. 2021 Jan;109(1):87-100
pubmed: 32449163
Int J Epidemiol. 2016 Dec 1;45(6):2075-2088
pubmed: 27375287
Clin Exp Immunol. 2022 Jun 11;208(2):220-232
pubmed: 35262683
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Stat Med. 2011 Oct 30;30(24):2867-80
pubmed: 21815180
Clin Trials. 2021 Oct;18(5):570-581
pubmed: 34269087
N Engl J Med. 2007 Nov 22;357(21):2189-94
pubmed: 18032770
Stat Methods Med Res. 2020 Mar;29(3):659-676
pubmed: 31456486
Endocr Pract. 2021 Apr;27(4):334-341
pubmed: 33685669
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:69-80
pubmed: 22552982
Curr Med Res Opin. 2014 Jun;30(6):1109-19
pubmed: 24517339
JAMA. 1991 Jul 3;266(1):93-8
pubmed: 2046134
BMJ. 2021 Jan 12;372:m4856
pubmed: 33436424
J Clin Epidemiol. 2018 Aug;100:22-31
pubmed: 29654822
Pharm Stat. 2021 Sep;20(5):939-944
pubmed: 33655601
Biostatistics. 2020 Jan 1;21(1):50-68
pubmed: 30052809
CMAJ. 2020 Aug 10;192(32):E901-E906
pubmed: 32778601

Auteurs

Jodi B Segal (JB)

Johns Hopkins University School of Medicine, Baltimore, and Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland (J.B.S., R.V.).

Ravi Varadhan (R)

Johns Hopkins University School of Medicine, Baltimore, and Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland (J.B.S., R.V.).

Rolf H H Groenwold (RHH)

Leiden University Medical Center, Leiden, the Netherlands (R.H.H.G.).

Xiaojuan Li (X)

Harvard Medical School Department of Population Medicine and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (X.L.).

Kaori Nomura (K)

Jikei University School of Medicine, Tokyo, Japan (K.N.).

Sigal Kaplan (S)

Teva Pharmaceutical Industries, Petah Tikva, Israel (S.K.).

Shirin Ardeshirrouhanifard (S)

Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland (S.A., J.H.).

James Heyward (J)

Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland (S.A., J.H.).

Fredrik Nyberg (F)

School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden (F.N.).

Mehmet Burcu (M)

Merck & Co., Rahway, New Jersey (M.B.).

Classifications MeSH